Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 10/20 | 0.67 |
| ▸ | P2RX2 | Q9UBL9 | 10/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171270 | 0.95 | P2RX3 (0.71) | P2RX3P2RX2 | |
| SCHEMBL1495662 | 0.89 | AKR1C3 (0.55) | P2RX3P2RX2HDAC1AKR1C3AKR1C4 | |
| SCHEMBL2173876 | 0.85 | P2RX3 (0.50) | P2RX3P2RX2HDAC1AKR1C3AKR1C4 | |
| SCHEMBL12757592 | 0.85 | P2RX3 (0.60) | P2RX3P2RX2AKR1C3 | |
| SCHEMBL12757691 | 0.85 | P2RX3 (0.60) | P2RX3P2RX2 | |
| SCHEMBL1495417 | 0.85 | P2RX3 (0.60) | P2RX3P2RX2 | |
| SCHEMBL1495539 | 0.85 | AKR1C3 (0.54) | P2RX3P2RX2HDAC1AKR1C3AKR1C4 | |
| SCHEMBL7946501 | 0.84 | HDAC1 (0.53) | P2RX3P2RX2HDAC1AKR1C3AKR1C4 | |
| SCHEMBL2383698 | 0.84 | AKR1C3 (0.53) | P2RX3P2RX2HDAC1AKR1C3AKR1C4 | |
| SCHEMBL2172216 | 0.83 | P2RX3 (0.53) | P2RX3P2RX2AKR1C3AKR1C4AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2346825-A2 | MODULATORS OF P2X3 RECEPTOR ACTIVITY | Evotec AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010033168-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | ADORA2B, IL1B, AVPR1B | P2RX3 207/4885P2RX2 240/4885HDAC1 560/4885 |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885HDAC1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.